TY - JOUR AB - Detecting malignant melanoma at an early stage, monitoring therapy, predicting recurrence and identifying patients at risk for metastasis continue to be a challenging and demanding objective. The last two decades have witnessed innovations in the field of melanoma biomarkers. However, global agreement concerning monitoring and early detection has yet to be reached. This is a review of the current literature regarding melanoma biomarkers including demographic, clinical, pathological and molecular biomarkers that are produced by melanoma or non-melanoma cells. A number of these biomarkers demonstrate promising results as possible methods for early detection, predicting recurrence and monitoring therapy. Other biomarkers appear to be promising for identifying patients at risk for metastasis. We reviewed the most pertinent information in the field thus far and how this knowledge can impact, or not, the management of melanoma patients prognostically and therapeutically. AD - Department of Internal Medicine, University of Missouri, Columbia, MO 65203, USA null AU - Al-Shaer,Mays AU - Gollapudi,Divya AU - Papageorgio,Chris DA - 2010/05/01 DO - 10.3892/ol_00000070 EP - 405 IS - 3 JO - Oncol Lett PY - 2010 SN - 1792-1074 1792-1082 SP - 399 ST - Melanoma biomarkers: Vox clamantis in deserto (Review) T2 - Oncology Letters TI - Melanoma biomarkers: Vox clamantis in deserto (Review) UR - https://doi.org/10.3892/ol_00000070 VL - 1 ER -